BenzingaBenzinga Korea 한국
BenzingaBenzinga Korea 한국
BenzingaBenzinga Korea 한국
목요일, 9월 17

BioMarin Pharmaceutical Inc

BMRNNASDAQ
Trade with Public
Trade with Public
$64.73
가까이에: Sep 17, 5:00 PM EST
$64.73
N/A
시간외: 4:00 PM EST
개요뉴스실적 전망이벤트목표가재무심리지분 현황비교옵션주식 보고서

BioMarin Pharmaceutical Analyst Price Targets

Wall Street analyst price targets and consensus rating for BioMarin Pharmaceutical (BMRN).

Price Target Range — 9 Quarters

Analyst Consensus — 29 Analysts

21Buy
8Hold
Consensus RatingBuy# Analysts29Avg. Consensus PT$91Upside to Avg. PT+40.3%

Rating Trend — Last 9 Months

Recent Analyst Actions

모든 평가 보기 →
DateFirmAnalystActionRating ChangePrice Target
Sep 10, 2026HC Wainwright & Co.Mitchell S. KapoorMaintainedNeutral$60
Sep 1, 2026Piper SandlerAllison BratzelPT RaiseOverweight$88→$90
More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
HC Wainwright & Co. Reiterates Neutral on BioMarin Pharmaceutical, Maintains $60 Price Target

HC Wainwright & Co. analyst Mitchell S. Kapoor reiterates BioMarin Pharmaceutical (NASDAQ:BMRN) with a Neutral and maintains $60 price target.
Benzinga Newsdesk

PRO
Piper Sandler Maintains Overweight on BioMarin Pharmaceutical, Raises Price Target to $90

Piper Sandler analyst Allison Bratzel maintains BioMarin Pharmaceutical (NASDAQ:BMRN) with a Overweight and raises the price target from $88 to $90.
Benzinga Newsdesk

PRO
Jefferies Maintains Buy on BioMarin Pharmaceutical, Raises Price Target to $105

Jefferies analyst Akash Tewari maintains BioMarin Pharmaceutical (NASDAQ:BMRN) with a Buy and raises the price target from $104 to $105.
Benzinga Newsdesk

PRO
HC Wainwright & Co. Maintains Neutral on BioMarin Pharmaceutical, Raises Price Target to $60

HC Wainwright & Co. analyst Mitchell S. Kapoor maintains BioMarin Pharmaceutical (NASDAQ:BMRN) with a Neutral and raises the price target from $59 to $60.
Benzinga Newsdesk

This Baidu Analyst Turns Bearish; Here Are Top 5 Downgrades For Wednesday

Wall Street analysts change outlook on top stocks, including BIDU and BMO. See their ratings and price targets on Benzinga's analyst page.
Avi Kapoor

This Alnylam Pharmaceuticals Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday

Top analysts change outlook on ALNY, AGMB, BMRN, BEKE, and IONS with ratings and price targets. Check out opinions and coverage on Benzinga.
Avi Kapoor

데이터 및 API: Benzinga API · 주식 뉴스 API · 애널리스트 등급 API · 회사 로고 API

시장 데이터 제공 Benzinga API

BenzingaBenzinga Korea 한국

뉴스

파트너 / 기고자

벤징가 글로벌

© 2026 Benzinga | All Rights Reserved